ULTRAGENYX PHARMACEUTICAL INC. Investing Cash Flow
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Investing Cash Flow of -$5.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $44.00M, a 38.03% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$49.00M, a 140.83% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$72.25M, a 170.48% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $117.25M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities for fiscal 2025 was $236.00M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities for fiscal 2024 was -$18.00M, a 110.71% decline from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities for fiscal 2023 was $168.00M.
- ULTRAGENYX PHARMACEUTICAL INC. net cash provided by (used in) investing activities for fiscal 2022 was -$291.65M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed | Net Cash Provided by (Used in) Investing Activities 47 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $44.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$5.00M 10-Q · filed 2026-08-05 | -$77.25M derived: sum of 3 quarters · filed 2026-08-05 | $40.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$49.00M 10-Q · filed 2026-05-06 | -$121.25M derived: sum of 2 quarters · filed 2026-05-06 | -$4.00M derived: sum of 3 quarters · filed 2026-05-06 | $67.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$72.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $45.00M derived: sum of 2 quarters · filed 2026-02-18 | $116.00M derived: sum of 3 quarters · filed 2026-08-05 | $236.00M 10-K · filed 2026-02-18 | ||||
| 2025-09-30 | $117.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $188.25M derived: sum of 2 quarters · filed 2026-08-05 | $308.25M 10-Q · filed 2025-11-05 | $410.75M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $71.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $191.00M 10-Q · filed 2026-08-05 | $191.06M 10-Q · filed 2025-08-06 | $293.50M derived: sum of 3 quarters · filed 2026-08-05 | $18.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $120.00M 10-Q · filed 2026-05-06 | $119.89M 10-Q · filed 2025-05-07 | $222.50M derived: sum of 2 quarters · filed 2026-05-06 | -$53.00M derived: sum of 3 quarters · filed 2026-05-06 | $7.57M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $102.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$173.00M derived: sum of 2 quarters · filed 2026-02-18 | -$112.44M derived: sum of 3 quarters · filed 2026-02-18 | -$18.00M 10-K · filed 2026-02-18 | -$17.77M 10-K · filed 2025-02-19 | |||
| 2024-09-30 | -$275.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$214.94M derived: sum of 2 quarters · filed 2025-11-05 | -$120.50M 10-Q · filed 2025-11-05 | -$227.52M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2024-06-30 | $60.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $155.00M 10-Q · filed 2025-08-06 | $47.98M derived: sum of 3 quarters · filed 2026-02-18 | $112.28M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2024-03-31 | $94.44M 10-Q · filed 2025-05-07 | -$12.58M derived: sum of 2 quarters · filed 2026-02-18 | $51.71M derived: sum of 3 quarters · filed 2026-02-18 | $151.13M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2023-12-31 | -$107.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$42.72M derived: sum of 2 quarters · filed 2026-02-18 | $56.70M derived: sum of 3 quarters · filed 2026-02-18 | $168.00M 10-K · filed 2026-02-18 | ||||
| 2023-09-30 | $64.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $163.71M derived: sum of 2 quarters · filed 2024-11-06 | $275.02M 10-Q · filed 2024-11-06 | $103.42M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | $99.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $210.72M 10-Q · filed 2024-08-02 | $39.12M derived: sum of 3 quarters · filed 2025-02-19 | -$122.74M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | $111.30M 10-Q · filed 2024-05-03 | -$60.30M derived: sum of 2 quarters · filed 2025-02-19 | -$222.15M derived: sum of 3 quarters · filed 2025-02-19 | -$142.99M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | -$171.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$333.46M derived: sum of 2 quarters · filed 2025-02-19 | -$254.29M derived: sum of 3 quarters · filed 2025-02-19 | -$291.65M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | -$161.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$82.69M derived: sum of 2 quarters · filed 2023-11-03 | -$120.05M 10-Q · filed 2023-11-03 | -$51.00M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $79.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $41.81M 10-Q · filed 2023-08-04 | $110.86M derived: sum of 3 quarters · filed 2024-02-21 | $70.10M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | -$37.36M 10-Q · filed 2023-05-05 | $31.70M derived: sum of 2 quarters · filed 2024-02-21 | -$9.06M derived: sum of 3 quarters · filed 2024-02-21 | -$50.31M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $69.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $28.30M derived: sum of 2 quarters · filed 2024-02-21 | -$12.95M derived: sum of 3 quarters · filed 2024-02-21 | -$195.37M 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | -$40.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$82.00M derived: sum of 2 quarters · filed 2022-11-03 | -$264.43M 10-Q · filed 2022-11-03 | -$166.53M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | -$41.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | -$223.67M 10-Q · filed 2022-07-29 | -$125.77M derived: sum of 3 quarters · filed 2023-02-17 | -$221.53M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | -$182.42M 10-Q · filed 2022-05-06 | -$84.52M derived: sum of 2 quarters · filed 2023-02-17 | -$180.28M derived: sum of 3 quarters · filed 2023-02-17 | -$266.42M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | $97.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $2.14M derived: sum of 2 quarters · filed 2023-02-17 | -$84.00M derived: sum of 3 quarters · filed 2023-02-17 | -$179.12M 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | -$95.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$181.90M derived: sum of 2 quarters · filed 2021-11-03 | -$277.02M 10-Q · filed 2021-11-03 | -$209.76M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-06-30 | -$86.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$181.26M 10-Q · filed 2021-08-03 | -$114.00M derived: sum of 3 quarters · filed 2022-02-15 | -$34.68M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-03-31 | -$95.13M 10-Q · filed 2021-05-05 | -$27.86M derived: sum of 2 quarters · filed 2022-02-15 | $51.45M derived: sum of 3 quarters · filed 2022-02-15 | -$6.97M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2019-12-31 | $67.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $146.58M derived: sum of 2 quarters · filed 2022-02-15 | $88.15M derived: sum of 3 quarters · filed 2022-02-15 | -$13.04M 10-K · filed 2022-02-15 | ||||
| 2019-09-30 | $79.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $20.89M derived: sum of 2 quarters · filed 2020-10-27 | -$80.31M 10-Q · filed 2020-10-27 | -$6.74M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-06-30 | -$58.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$159.62M 10-Q · filed 2020-07-30 | -$86.06M derived: sum of 3 quarters · filed 2021-02-12 | -$69.85M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-03-31 | -$101.19M 10-Q · filed 2020-05-07 | -$27.63M derived: sum of 2 quarters · filed 2021-02-12 | -$11.43M derived: sum of 3 quarters · filed 2021-02-12 | -$63.50M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2018-12-31 | $73.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $89.77M derived: sum of 2 quarters · filed 2021-02-12 | $37.70M derived: sum of 3 quarters · filed 2021-02-12 | -$33.33M 10-K · filed 2021-02-12 | ||||
| 2018-09-30 | $16.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$35.86M derived: sum of 2 quarters · filed 2019-11-06 | -$106.89M 10-Q · filed 2019-11-06 | -$49.50M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-06-30 | -$52.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$123.10M 10-Q · filed 2019-08-02 | -$65.71M derived: sum of 3 quarters · filed 2020-02-14 | -$35.92M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-03-31 | -$71.03M 10-Q · filed 2019-05-07 | -$13.64M derived: sum of 2 quarters · filed 2020-02-14 | $16.15M derived: sum of 3 quarters · filed 2020-02-14 | |||||
| 2017-12-31 | $57.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $87.18M derived: sum of 2 quarters · filed 2020-02-14 | $55.48M 10-K · filed 2020-02-14 | |||||
| 2017-09-30 | $29.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$1.91M 10-Q · filed 2018-11-06 | ||||||
| 2017-06-30 | -$31.70M 10-Q · filed 2018-08-03 | |||||||
| 2016-12-31 | $91.12M 10-K · filed 2019-02-20 | |||||||
| 2014-09-30 | -$13.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$41.02M derived: sum of 2 quarters · filed 2014-11-10 | -$106.42M 10-Q · filed 2014-11-10 | |||||
| 2014-06-30 | -$27.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$92.87M 10-Q · filed 2014-08-11 | ||||||
| 2014-03-31 | -$65.40M 10-Q · filed 2014-05-12 | -$115.32M 10-Q · filed 2014-05-12 | ||||||
| 2013-09-30 | -$787.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$43.75M derived: sum of 2 quarters · filed 2014-11-10 | -$58.85M 10-Q · filed 2014-11-10 | |||||
| 2013-06-30 | -$42.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$58.06M 10-Q · filed 2014-08-11 | ||||||
| 2013-03-31 | -$15.10M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |